Clinical Trials in Detroit

Showing 15801-15820 of 19,719 trials

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00085254

Cilengitide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving cilengitide together with temozolomide and radiation therapy may kill more tumor cells. This randomized phase I/II trial is studying the side effects and best dose of cilengitide when given together with temozolomide and radiation therapy and to compare how well they work in treating patients with newly diagnosed glioblastoma multiforme

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma

National Cancer Institute (NCI)112 participantsStarted Apr 2005

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 4< 1 mile

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Hepatitis C, Chronic

Hoffmann-La Roche1,469 participantsStarted Dec 2003

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +129 more locations

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Find Trials by Condition in Detroit

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Biological Therapy in Treating Women With Stage IV Breast Cancer

Blood and Marrow Transplant Clinical Research Network

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

Imatinib (QTI571) in Pulmonary Arterial Hypertension

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Proximal Protection With The Mo.Ma Device During Carotid Stenting

Safety of Gadovist in Renally Impaired Patients

Cervical Preparation Before Dilation and Evacuation

Intradiscal rhGDF-5 Phase I/II Clinical Trial

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Glucose Meter Study